Ginkgo Bioworks Holdings Inc
For the period ended Dec 31, 2023. Filed Feb 29, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Feb 29, 2024
DNA$12.01-2.9%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statements of Operations and Comprehensive Loss
(in thousands, except per share data)
| Year Ended December 31, | |||
|---|---|---|---|
| 2023 | 2022 | 2021 | |
| Cell Engineering revenue (1) | $143,531 | $143,666 | $112,989 |
| Biosecurity revenue: | |||
| Product | 28,949 | 35,455 | 23,040 |
| Service | 78,975 | 298,585 | 177,808 |
| Total revenue | 251,455 | 477,706 | 313,837 |
| Costs and operating expenses: | |||
| Cost of Biosecurity product revenue | 7,481 | 20,646 | 20,017 |
| Cost of Biosecurity service revenue | 46,524 | 183,570 | 109,673 |
| Research and development | 580,621 | 1,052,643 | 1,149,662 |
| General and administrative | 385,025 | 1,429,799 | 862,952 |
| Impairment of lease assets | 96,210 | — | — |
| Total operating expenses | 1,115,861 | 2,686,658 | 2,142,304 |
| Loss from operations | (864,406) | (2,208,952) | (1,828,467) |
| Other income (expense): | |||
| Interest income | 57,217 | 20,262 | 837 |
| Interest expense | (93) | (106) | (2,373) |
| Loss on equity method investments | (2,635) | (43,761) | (77,284) |
| Loss on investments | (54,827) | (53,335) | (11,543) |
| Change in fair value of warrant liabilities | 5,168 | 124,970 | 58,615 |
| Gain on settlement of partnership agreement | — | — | 23,826 |
| (Loss) gain on deconsolidation of subsidiaries | (42,502) | 31,889 | — |
| Other income (expense), net | 9,138 | 7,634 | (1,733) |
| Total other income (expense), net | (28,534) | 87,553 | (9,655) |
| Loss before income taxes | (892,940) | (2,121,399) | (1,838,122) |
| Income tax benefit | (71) | (15,027) | (1,480) |
| Net loss | (892,869) | (2,106,372) | (1,836,642) |
| Loss attributable to non-controlling interest | — | (1,443) | (6,595) |
| Net loss attributable to Ginkgo Bioworks Holdings, Inc. stockholders | $(892,869) | $(2,104,929) | $(1,830,047) |
| Net loss per share attributable to Ginkgo Bioworks Holdings, Inc. common stockholders: | |||
| Basic | $(0.46) | $(1.25) | $(1.35) |
| Diluted | $(0.46) | $(1.25) | $(1.39) |
| Weighted average common shares outstanding: | |||
| Basic | 1,944,420 | 1,679,061 | 1,359,849 |
| Diluted | 1,944,420 | 1,679,839 | 1,360,373 |
| Comprehensive loss: | |||
| Net loss | $(892,869) | $(2,106,372) | $(1,836,642) |
| Other comprehensive loss: | |||
| Foreign currency translation adjustment | 4,116 | (917) | (1,715) |
| Total other comprehensive gain (loss) | 4,116 | (917) | (1,715) |
| Comprehensive loss | $(888,753) | $(2,107,289) | $(1,838,357) |
(1)Includes related party revenue of $22,222, $38,813, and $47,161 for the years ended December 31, 2023, 2022, and 2021, respectively.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.